A multi-center, double-blind, placebo-controlled, randomized, parallel-group study to investigate the safety and efficacy of JNJ 31001074 in adults with attention-deficit/hyperactivity disorder

Trial Profile

A multi-center, double-blind, placebo-controlled, randomized, parallel-group study to investigate the safety and efficacy of JNJ 31001074 in adults with attention-deficit/hyperactivity disorder

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jun 2014

At a glance

  • Drugs Bavisant (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 04 May 2010 Actual patient number (32) added as reported by ClinicalTrials.gov.
    • 04 May 2010 Actual patient number (32) added as reported by ClinicalTrials.gov.
    • 01 Oct 2008 checked against clinicaltrials.gov record: added Association (Johnson and Johnson).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top